SCHEDULE: Vanguard Group Reports 0% Stake in Nurix Therapeutics

The Vanguard Group has reported a 0% beneficial ownership in Nurix Therapeutics Inc. common stock following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Nurix Therapeutics Inc.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Nurix Therapeutics Inc. common stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions will report beneficial ownership separately, and The Vanguard Group, Inc. no longer has beneficial ownership over those securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative development for Nurix Therapeutics Inc. as a significant institutional investor, The Vanguard Group, has reduced its reported beneficial ownership to 0%, even if due to internal realignment, which could impact investor perception.

Negatives

• The Vanguard Group, a significant institutional investor, now reports 0% beneficial ownership in Nurix Therapeutics Inc.
• This reduction in reported ownership could be perceived negatively by the market, as it indicates a major institutional holder no longer directly holds a reportable stake.

Risks

• Potential negative market perception due to a major institutional investor, The Vanguard Group, reporting 0% beneficial ownership.
• Reduced institutional investor presence could impact stock liquidity or investor confidence.

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially from large asset managers like The Vanguard Group, are closely watched by the market. While this filing attributes the change to an internal realignment, it still signifies a shift in how Vanguard's overall exposure to Nurix Therapeutics is reported, potentially influencing investor sentiment regarding the stock's institutional backing.

Stakeholder Impact

• Shareholders: May perceive a reduction in institutional interest, potentially leading to negative sentiment or price pressure.
• Investors: Will note the change in institutional ownership structure, potentially re-evaluating their own positions.

Key Dates

Recommendation

The Vanguard Group's reported 0% beneficial ownership, despite being attributed to an internal realignment, removes a significant institutional holder from Nurix Therapeutics Inc.'s public ownership records. This could be interpreted by the market as a reduction in institutional support or interest, potentially leading to negative investor sentiment and downward pressure on the stock price. Seasoned investors would likely view this as a signal to reduce or exit positions, anticipating potential negative market reaction.

Keywords

Nurix Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, NXTP